关于神经精神病药物开发的公私伙伴关系:一个前景
1Independent Expert, Philadelphia, PA, USA.
Advances in neurobiology
|November 19, 2024
概括
公私伙伴关系 (PPP) 对于开发神经精神疾病生物标志物至关重要. 阿尔茨海默病神经成像计划 (ADNI) 是成功验证生物标志物的典范,是未来中枢神经系统药物开发工具的典范.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 药物开发 药物开发
背景情况:
- 开发神经精神疾病的生物标志物是具有挑战性的,因为研究范围有限,缺乏大规模的验证网络.
- 阿尔茨海默病神经成像计划 (ADNI) 成立于2004年,开创了用于生物标志物验证的公私合作伙伴关系 (PPPs),重点是阿尔茨海默病中的粉样沉积.
研究的目的:
- 审查阿尔茨海默病神经成像计划 (ADNI) 在过去二十年中的进展和影响.
- 讨论在生物标志物研究中成功开发PPP的关键组成部分.
- 突出PPP在促进中枢神经系统 (CNS) 药物开发中的关键作用.
主要方法:
- 审查ADNI的成就和正在进行的工作.
- 对PPP的基本要素的分析:利益相关者识别,治理,资金和数据共享.
- 将ADNI的模型与最近的PPP相比较.
主要成果:
- 在开发粉样蛋白沉积物作为阿尔茨海默病的生物标志物方面,ADNI取得了重大进展.
- 建立了成功的PPP的关键组成部分,为新举措提供了参考.
- 证明了PPP在解决竞争前生物标志物研究的高投资需求方面的价值.
结论:
- 以ADNI为例的PPP对于克服神经精神疾病生物标志物开发的局限性至关重要.
- 有效的PPP需要强大的利益相关者参与,治理,资金和数据可访问性流程.
- 公共公共合作提供了一个重要的途径,用于创建下一代工具,以加速中枢神经系统药物开发.
相关概念视频
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104
Drug Administration and Therapy Phases: Overview
409
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
409


